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Cancer is a debilitating disease resulting from uncontrolled proliferation.  One major 
treatment strategy for cancer is the application of chemotherapeutic drugs which kill cancer cells.    
Cucurbitacins are a new family of plant-derived drugs that are being researched for their 
potential cytotoxic effects against cancer cells.  All cucurbitacins have shared an anti-cancer 
activity stemming from their inhibitory effects on Janus kinase 2 (JAK2)/signal transducer and 
activator of transcription 3 (STAT3) signaling.  Cucurbitacin IIa (Cuc IIa) is the newest 
compound to be characterized in this family.  The purpose of this thesis is to investigate the anti-
cancer properties of Cuc IIa.  Cuc IIa was used to treat mice that had been injected with Lewis 
Lung cancer cells.  These animal studies show that Cuc IIa had reduced the tumor size without 
any weight change within the mouse.  Furthermore, Cuc IIa displays anti-cancer activity against 
prostate cancer cell lines, PC3 and Rv1, and lung cancer cell line NCI-H1299.   Cuc IIa is shown 
to induce apoptosis through actin clustering.  In addition, Cuc IIa induces apoptosis through the 
increase in cleaved PARP expression and a reduction in phospho-Histone H3 expression.  Cuc 
IIa induces cell cycle arrest at the G2/M phase of the cell cycle.  While other members of the 
Cucurbitacin family express anti-cancer activity through effects on the JAK2/STAT3 pathway, 
Cuc IIa does not share this feature.  Western blot staining for JAK2 and STAT3 proteins reveal 
that Cuc IIa exterts no direct effect JAK2/STAT3 phosphorylation.  Instead, Cuc IIa inhibits 
 survivin downstream of JAK2/STAT3 phosphorylation. Therefore, this thesis highlights a unique 
Cuc compound with the potential to become a powerful anti-cancer agent not working at the 
level of JAK2/STAT3 activation which is commonly found in other Cucurbitacins. This feature 
may provide a new mechanistic point of anti-cancer drug action to combat drug resistance. 
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Chapter 1: Project Summary 
Plants are outstanding sources of medicinal chemicals that can inhibit cancer, a deadly 
disease yet to be conquered.  Cucurbitacin (Cuc) and triterpene derived natural products exhibit 
anti-cancer potential in addition to their conspicuous anti-bacterial and anti-inflammatory 
activity. Recently, inhibition of JAK2/STAT3 signaling was shown to underlie the effects of 
Cucurbitacin family members on inducing cell death in many cancer types.  Cells have multiple 
mechanisms for activating apoptosis including activation of the Caspase cascade and inhibition 
of JAK/STAT pathway.  Cleavage of Poly (ADP-ribose) polymerase or PARP, immediate 
upstream of DNA breakdown as a result of caspase activation, is known to increase dramatically.  
However, while an increase of apoptosis was indicated through PARP cleavage, in regards to 
JAK/STAT there was no indication that Cucurbitacin cytotoxicity stemmed from the inhibition 
of this pathway.  
Here, I hypothesize that Cucurbitacin IIa (or Cuc IIa), the active component purified from 
the medicinal plant Hemsleya amabilis Diels, inhibits cancer cell growth, induces apoptosis, and 
reduces tumor growth in vivo.  The project was to test this hypothesis and investigate the 
molecular mechanisms by which Cuc IIa exerts its anti-cancer effects. 
I investigated if Cuc IIa is cytotoxic against cancer cells and if the cytotoxic activity 
stems from acting upon the actin cytoskeleton. I found that Cuc IIa induced the irreversible 
clustering of filamentous actin and the increases in G2/M cell populations in cell cycle, 
indicating the disruption of actin cytoskeleton as the likely mechanism of inducing apoptosis, 
specifically during mitosis.   
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To better understand the mechanisms of Cuc IIa’s cytotoxicity, I focused on cell culture 
experiments and protein expression analysis of cell cycle and apoptosis.  Prostate cancer cell 
lines, CWR22Rv-1 and PC3, and the lung cancer cell line H1299, were utilized in this study.  I 
confirmed the Cuc IIa cytotoxicity using the cell viability assay to record a reduction in 
metabolic activity for cells treated with Cuc IIa.  The reduced metabolism is used as an 
indication of cell death based on the difference of metabolic activity between non-treated and 
Cuc-treated cells. 
I also studied the molecular and cellular target mechanisms used by Cuc IIa by 
immunofluorescence and western blotting analysis.  It has been reported that the cytotoxicity of 
Cucurbitacins stem from interactions with the cytoskeletal proteins actin and microtubule 
network.  Fixed cells stained with actin and tubulin markers indicated an alteration of 
filamentous actin but not tubulin, as the main cause in association with apoptotic cells.  
Additional immunofluorescent studies focused on the expression and distribution of MAPK, Rho 
A and STAT-3 proteins.  These proteins are integral in survival and apoptotic pathways.  The 
expression and localization of these proteins under Cuc IIa treatment have shown indications that 
apoptosis is induced independent of the JAK/STAT pathway.  Finally, the Western blot studies 
of protein expression from the cell lysates confirmed apoptosis by the increased expression of 
cleaved PARP and a reduction in phopsho-Histone H3 and survivin.   
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Chapter 2: Introduction 
 
 
Cancer is a debilitating disease that arises from dysfunction of many critical cellular 
checkpoints (Maddika et al., 2007).  Two hallmarks of cancer are the uncontrolled proliferation 
of cells and suppression of apoptosis (Evan and Vousden, 2001; Ghavami et al., 2009; Liu et al., 
2011).  The uncontrolled proliferation typical of cancer cells is a result of defects in the 
regulatory pathways (Hanahan & Weinberg, 2000).  Cell survival pathways, such as JAK/STAT, 
are commonly over-expressed in neoplasia contributing to oncogenesis (Benekli et al., 2009; 
Aggarwal et al., 2006; Glienke et al., 2010).  Many cancers are initiated through some type of 
cellular damage either by UV radiation, or cellular stresses.  
Mutations in standard cell regulation systems can induce cancer cells to divide without 
control.  It is the continuous division of tumor cells and their metastatic abilities that causes 
cancer to be so difficult to treat.  Chemotherapy drugs are developed with the inhibition of rapid 
division of cancer cells in mind and induce apoptosis in cancerous cells (Johnstone et al., 2002).  
The goal of chemotherapeutics is the induction of apoptosis (Longley and Johnstone, 2005).  
Chemotherapeutics are designed to target specific pathways within the cell, such as inhibiting 
JAK2/STAT3 (Cucurbitacin I and Cucurbitacin Q) (Shi et al., 2006; Sun et al., 2005).  The 
inhibition of survival pathways and activation of apoptotic pathways are the main targets for 
developing treatments for cancer (Evan and Vousden, 2001).   
Currently, there is a wide variety of treatment options for different cancer types, with 
chemotherapy being the most effective.  Chemotherapeutics work in several different ways.  
Many act on the cytoskeletal proteins actin and microtubules to induce apoptosis through the 
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arrest of mitosis, e.g. taxanes on polymerization of microtubules (Jordan and Wilson, 2004) and 
Cuc E by disruption of actin (Duncan et al., 1996; Duncan and Duncan, 1997).  However, severe 
drawbacks of common chemotherapeutics are their harsh side effects and non-specific targeting.  
Due to the detrimental side effects, drugs must be administered in rounds with frequent periods 
of rest in order for the patient to recuperate.  These breaks are necessary but they carry the 
possibility for the cancers to undergo further mutations and acquire a resistance to the 
chemotherapy drugs.  This high level of resistance for cancers, most notable for solid tumors, 
demands several highly toxic drugs to be used, again causing severe and painful side effects.  
Chemotherapy drugs are developed based on the faster proliferation rate for cancer cells as 
opposed to somatic cells (Johnstone et al., 2002).  Although chemotherapeutics are effective 
treatments for neoplastic tissues they also target other rapidly dividing cells, including the cells 
lining the gut, inside the mouth and rapidly dividing white blood cells.     
The categories of chemotherapeutics fall under three categories: alkylating agents, 
microtubule targeting, and inducers of apoptosis through anti-survival or pro-apoptotic pathways.  
Alkylating agents include cisplatin type drugs.  Cisplatin eradicates cancer cells by cross-linkng 
the cytosine and guanine nucleotide bases within the cell’s DNA, an action preventing the cell 
from proper replication for cellular division (Brabee 1993; Brozovic and Osmak 2007).  This 
cross linking induces apoptosis in the cell by arresting the cell in G1/S transition of the cell cycle 
through activation of checkpoints (Gibb et al., 1997).  Microtubule targeting drugs include 
vincristine, vinblastine, and paclitaxa, or taxoll (Torres & Horwitz 1998; Shi 2008).  Paclitaxal, 
derived from the Taxus brevifolia Nutt, blocks polymerization of microtubules essential for 
mitotic spindle formation, resulting in the cell arrest in G2/M phase of the cell cycle (Bhalla 
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2003; Lanzi et al., 2001; Mukherjee et al., 2001).  By arresting the cell in mitosis, the cell cycle 
checkpoints are activated inducing the cell to undergo apoptosis. 
There are several categories for chemotherapy drugs based on the principles of inducing 
apoptosis in tumor cells or reducing proliferation (Tennant 2010).  These actions are performed 
by blocking a specific pathway in the cell.  One attractive signaling pathway to block is 
JAK/STAT pathway.  This has been one of the most successful pathways to be targeted by 
chemotherapy drugs (Aggarawal 2006).  Another pathway to induce apoptosis is through the 
Caspase-3/PARP pathway which is activated by cleaved caspase-3 which in turn de-activates 
PARP (Oliver et al., 1998). 
In order to better tailor chemotherapy to target cancer cells and overlook normal tissues, 
many drugs are selected based on characteristics unique to cancer cells.  Such characteristics 
include over-expressed survival pathways (e.g. JAK/STAT), disabled apoptotic pathways (e.g. 
PARP), and increased cellular division through disabled cellular checkpoints.  The JAK pathway 
is a key pathway to be targeted because this is a survival pathway that cancer cells use to avoid 
apoptosis to continue proliferation.  In many cancers, the STAT pathway is constitutively active, 
thus transcribing survival proteins such as survivin which assists in avoiding apoptosis.  It is 
assumed that chemotherapy drugs that target the JAK/STAT pathway prevents the inhibitors of 
apoptosis from being transcribed, and ceases transcription of the proliferation proteins.  The 
development of chemotherapy drugs has focused on survival and apoptotic pathways such as 
STAT3 and PARP, respectively.  It has been found that one of the most successful target 
pathways is STAT3.  By focusing on inhibiting STAT3, researchers have devised a method to 
induce apoptosis for cancer specific cells.   
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Another well documented signaling cascade that is affected in many cancers involves PARP 
as an inducer of apoptosis.  The main protein in this pathway, PARP, is responsible for repairing 
damaged DNA within the cell (Oliver et al., 1998; Augustin et al., 2003).  Through caspase 
cleavage, PARP can disable critical protein and induces apoptosis.  PARP is cleaved by effector 
caspases which are themselves cleaved by initator caspases (Boulares et al., 1999).  Caspase-3, 
which is responsible for PARP cleavage, is activated by Caspase-9 (Cagnol and Chambard 2009; 
Ndozangue-Touriguine et al., 2008).   
Many anti-mitotic drugs target the cytoskeletal proteins such as microtubules and actin (Shi 
et al., 2008; Gascoigne and Taylor, 2009).  Some of them are plant derived drugs, including 
paclitaxal and other vinca alkaloids (such as vincristine and vinblastine) (Jordan and Wilson, 
2004).  These drugs are successful due to their actions on microtubules by inhibiting 
polymerization dynamics (Bhalla, 2003).  It has been shown that anti-mitotics induce apoptosis 
by triggering activation of caspase cascade and PARP. 
For thousands of years, many cultures have used plant derived medicines for common 
illnesses (Ríos 2009; Pezzuto, 1997).  Recently, new chemotherapy drugs have emerged that are 
derived from natural sources.  Lately there has been an increase in the use of naturally derived 
chemotherapy drugs that are growing in popularity due to their reduced incidence of side effects 
and the multiple pathways these natural drugs affect (Pezzuto 1997; Wu et al., 2002).  Several 
effective drugs include Paclitaxal (Taxus brevifolia L.), Vincristine (Catharanthus roseus G. 
Don), podophyllotoxin (Podophyllum peltatum L.), and camptothecin (Camptotheca acuminate 
Decne) (Pezzute, 1997; Kavallaris 2010).  Some of the well known plant-derived chemotherapy 
drugs are also known to work on the cytoskeleton.  For example, vincristine works to 
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depolymerize tubulin while taxol works to stabilize tubulin and cucurbitacin E disrupts the actin 
cytoskeleton (Momma 2008; Duncan et al., 1996; Duncan et al., 1997; Shi et al., 2008). 
The Cucurbitacin compounds are a group of tetracyclic triterpenoids from the cucurbitane 
skeleton derived mostly from the cucurbitacae family (Haritunians et al., 2008; Chen et al., 
2005).  Cucurbitacins are characterized by the tetracyclic cucurbitane nucleus skeleton 9β-
methyl-19-nor lanosta-5-ene (Figure 1) with a variety of oxygen substitutions at varying 
locations (Chen et al., 2005; Tannin-Spitz et al., 2007).  Cucurbitacins are a new family of 
naturally derived drugs found in various types of plants and roots across the planet (Graness et 
al., 2006).  The most recent discoveries have identified at least 19 Cucurbitacins ranging from A 
to S (Chen et al., 2008) which are each distinct within the family and perform a unique function 
within the cell. Each Cucurbitacin is characterized based on the cytotoxicity level and the 
cellular signaling pathway it targets (Chen et al., 2005).  Interestingly, the majority of the 
Cucurbitacins have been shown to possess anti-tumor properties (Chen et al., 2008).  It has been 
discovered that most Cucurbitacins induce apoptosis through the JAK/STAT pathway (Tannin-
Spitz et al., 2007; Chen et al., 2005).  Cucurbitacin compounds, including Cucurbitacin B, are 
highly selective for the STAT3 pathway, having little to no effect on other cell survival pathways 
(Graness et al., 2006; Ríos et al., 2009; Thoennissen et al., 2009). Cucurbitacin I inhibits growth 
of cancer cells with active STAT-3 (Nefedova et al., 2005).   
Cuc IIa (25-acetoxy-23,24-dihydrocucurbitacin F, also called hemslecin A; Figure 2), the 
active component purified from the medicinal plant Hemsleya amabilis Diels, is a member of the 
Cucurbitacin F family (Chen et al., 2005), which has been shown to polymerize tubulin 
(Maloney et al., 2008).  In recent literature, inhibition of JAK2/STAT3 signaling was shown to 
underlie the effects of Cuc family members on inducing cell death in many cancer types.    
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Cuc IIa is a triterpene family component of natural products with different structural 
modifications from other Cuc derivatives.  The plant has been used as a homeopathic treatment 
for various diseases in China for centuries and has been indicated to display anti-cancer potential 
(Wu et al, 2002).  However, the molecular and cellular mechanisms of its anti-cancer activities 
have not been established. 
Cuc IIa has been tested for initial cytotoxic effects against cancer cells within animal models, 
where it has been shown to be effective at reducing tumor growth.  Zhang et al (2006) tested 
efficacy of Cuc IIa treatment in a group of mice injected with H22 liver cancer cells and a group 
of mice injected with Lewis Lung cancer cells.  When Cuc IIa was given to the mice by either 
oral, peritoneal and intravenous injections, it resulted in consistently reduced tumor size.  
However, the most efficient method for introduction of Cuc IIa was shown to be through 
intravenous injection.  In our preliminary studies, Cuc IIa suppressed cancer cell growth in a 
dose dependent manner in cell culture.  The focus of this thesis is to better understand the 
mechanisms by which Cuc IIa exhibits its toxicity toward cancer cells. 
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Chapter 3: Methodology 
 
Cell Culture 
Human cancer cell lines NCI-H1299 (lung cancer), PC3 (metastatic prostate cancer), and 
CWR22-Rv1 (prostate tumor xenograft derived cells), as well as mouse fibroblast NIH3T3 were 
maintained at 37°C at 5% CO2 environment.  The cells are grown in media consisting of RPMI 
1640 with 10% Fetal Bovine Serum, and 1% Penicillin/Streptomycin.  Some of the cells used 
have been transfected.  These cells require 0.25% Geneticin to be included in the media.  The 
cells will be split at a 1,000 cell density into 96-well plate for MTT assay.  The density will 
range from 10,000 to 100,000 cells grown in 60 mm culture dishes for transfections and 
immunofluorescence studies. 
 
Cell Proliferation assay 
The cells were plated into 96-well trays at a density of 1,000 cells/well and were grown for 
two days.  The cells were treated with the following drugs at Cuc IIa (1, 10, and 100μg/mL), 
Cisplatin (8, 16, and 32 μg/mL) and Paclitaxel (1, 5, and 10mM) for 48hrs.  Then, the cells were 
incubated in MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (ACROS).  
Following 3 hour incubation with MTT, 100% Dimethyl Sulfoxide (DMSO) was applied to lyse 
the cells and release the formazan purple crystal product.  The amount of formazan was read at 
an absorbance of 562nm by a microplate reader (Synergy HT, Bio-Tek). 
 
Cell Growth Assay 
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In order to record the amount of cell growth over time, H1299 cells were plated into a 12-
well tray at 1,000 cells/well.  The H1299 cells were treated with Cuc IIa 1 μg/mL, Cuc IIa 10 
μg/mL and one set with no treatment.  The cells were measured by counting the number of cells 
in each well on days 4, 6, and 8.  The cells were lifted using 0.25% Trypsin and counted using 
Countess Hematocytometer (Invitrogen).  The amount of cell growth was recorded and then 
analyzed using Sigma Plot.   
 
Flow Cytometry 
H1299 cells were plated into 60 mm culture plates at a density of 50,000 cells/plate and 
grown for two days.  The cells were then treated with Cuc IIa at 10 μg/mL for 6hr and 16hr, 
respectively.  Afterwords, the cells were collected for flow cytometry analysis using FlowScan.  
Specifically, following the 6hr and 16hr treatment, the cells were lifted off the plate using 0.25% 
Trypsin (GIBCO) for 5min at 37°C.  The cells were collected into a 15ml tube and spun down at 
1,000 rpm for 5min in order to pellet the cells.  After which, the supernatant was discarded and 
the cells were re-suspended in 300μl of Phosphate Buffered Saline (PBS) and 700 μl of 100% 
ethanol, then stored in -20°C.  To stain the nuclei, the cells are removed from the freezer and 
spun down at 1,000 rpm for 5min to pellet the cells then remove the supernatant.  The cells are 
washed with PBS one time followed by centrifuge to remove the supernatant.  Then the cells are 
re-suspended in 500 μl Propidium Iodide staining solution (470 μl Phosphate Buffered Saline, 
5μl RNase A, and 25 μl of 1 mg/mL Propidium Iodide).  The cells were incubated in the stain for 
30min at 37°C followed by 1hr incubation at room temperature making sure to avoid light.  The 
DNA content for PI stained cells was analyzed on a FACScan (BD Biosciences, Palo Alto, CA, 
USA) at 488nm excitation and emission detected using a 585nm band pass filter.  The percentage 
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of cells in each phase of cell cycle (SubG1, G1, S and G2/M) was determined using a ModFit 3.1 
computer program (Varity Software House, Topsham, ME, USA).  The results were analyzed by 
taking the mean and standard error results for each phase. 
 
Immunofluorescent stain for apoptotic proteins 
Cells are seeded on coverslips in a 24-well plate for two days.  The cells were then treated 
with Cuc IIa at 1, 10 and 50 μg/mL for two days.  The cells were fixed using 4% 
Paraformaldehyde for 20 minutes followed by two washes with PBS, and then the coverslips will 
be stored in PBS at 4°C.  Following permeabilisation with 0.2% Triton for 15 minutes, the cells 
were rinsed with PBS.  The coverslips were incubated in 100mM glycine for 10 minutes 
followed by a single wash with PBS.  The coverslips were then blocked with 10% BSA for 30 
minutes at 37°C.  Immediately after blocking, the cells were incubated with primary antibody 
diluted in 1% BSA for 1 hour at room temperature.  The primary antibody will be washed off 
using 1% Bovine Serum Albumin (Sigma) in PBS three times for five minutes apiece followed 
by incubation with the appropriate secondary antibody for 1 hour at room temperature.  The 
secondary antibody was washed off with three washes of PBS at five min apiece.  After the 
secondary is washed off, the nuclei of the cells were stained with 2μg/mL Hoechest for 1 minute.  
The coverslips were mounted on microscope slides using AntiFade medium (Molecular Probe).   
The proteins that were stained for indicating apoptosis will be JAK2 (1:100), STAT-3 
(1:100), and phsopho-Histone H3 (1:100).  The secondary antibodies for the primary antibodies 
were either Cy3 conjugated goat anti-rabbit mouse IgG or Cy3 conjugated AffiniPure Donkey 
Anti-Mouse IgG (Jackson ImmunoResearch Laboratories, Inc.). 
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Western Blot analysis of apoptotic and cell proliferation proteins 
Proteins were probed using Western blotting method from cell lysates treated with or without 
Cuc IIa.  The cells were grown to 80% confluence in 60 mm culture dishes after which the cells 
were treated with Cuc IIa at 1 and 10μg/mL for 24hrs.  Following treatments, the cells were 
lysed.  The cells were lifted using RIPA Lysis Buffer (Pepstatin A, Complete tablet of protease 
inhibitor, and RIPA Buffer – Triton, Sodium Deoxycholate, Sodium Dodecyl Sulfide, Sodium 
Chloride, Ethylenediamine Tetraacetic Acid, and HEPES).  The cells were lysed by passing the 
collected cells through a 22G needle on a 1cc syringe to break up the cells and release the 
protein.  The lysed cells were incubated on ice for 30 minutes followed by centrifugation at 
14,000rpm at 4°C for 30min.  The supernatant is transferred to a new tube and the protein 
concentration was analyzed.  The protein concentration of the cells was determined using the 
BCA assay.  The lysates were diluted in water and tested against a standard curve BCA 
concentration.  The lysates were diluted in water and tested against a standard curve of BCA 
concentrations. The lysates and standards were incubated in the BCA kit working solution 
(Thermo Scientific) for 30min at 37°C followed by 30min incubation at room temperature to 
cool the solutions.  The protein concentrations were determined by reading at 560nm in a 
microplate reader (BioTek Synergy). 
The lysates were run on an 8-16% Tris-Glycine gel in Tris-Glycine running buffer 
immediately followed by transferring the gel to Nitrocellulose Membrane at 250mA and 90V for 
a pre-determined timeframe.  The membranes were blocked in 5% Bovine Serum Albumin for 
phosphorylated antibodies and 5% milk for all other antibodies for 1 hour at room temperature.  
The membranes were incubated with primary antibody at 4°C overnight.  The membranes were 
washed three times with 0.1% Tween-20 in Tris Buffered Saline (TBST) and incubated on 
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appropriate secondary antibody for 1 hour at room temperature.  The membranes were incubated 
on ECL detection reagent for 1 minute, then exposed to film and developed.  The antibodies 
were PARP, cleaved PARP, phospho-Histone H3, JAK2, STAT3, phospho-STAT3, caspase-3, 
cleaved caspase-3, and Histone H3.  Band density was measured and analyzed using Quantity 
One (Bio-Rad laboratories).  The densities were analyzed in triplicate and the results were 
averaged and graphed in a chart (Figure 9-right). 
 
Immunofluorescent light microscopy of cytoskeletal proteins actin and tubulin 
The cells on coverslips were incubated with 0.2% Triton to permeabilize the cells, and the 
cells were washed with PBS.  They were incubated with 100mM Glycine at room temperature, 
followed by rinses with PBS.  The cells were then incubated with Rhodamine Phalloidin (1:400) 
at room temperature for 30 minutes.  The cells were stained for tubulin using α-tubulin as the 
primary antibody, using the same method as previously stated when staining for apoptotic 
proteins.  After the coverslips were rinsed three times with PBS, and incubated with 2μg/mL 
Hoechest, they were mounted on microscope slides using Anti-Fade medium. 
 
Cucurbitacin IIa Molarity 
Cucuribtacin IIa has a formula weight of 562.73 g/mol.  The concentrations used in this study 
were 1μg/mL, 10 μg/mL, and 50 μg/mL.  In molar concentrations, this equates to 1.8nM, 18nM, 
and 89nM, respectively.  An effective cancer drug is defined as one which has a strong cytotoxic 
effect at the lowest concentrations possible.  Since I have been able to see Cuc IIa induce 
cytotoxicity in concentrations of nM, this indicates that Cuc IIa could have the potential to be a 
very powerful tool to combat cancer. 
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Chapter 4: Specific Aims 
 
Specific Aim #1: To investigate the cytotoxic action of Cuc IIa on cancer cells.  
The purpose of this aim is to discover the pathways Cuc IIa effects on the cancer cells.  
Two pathways that I focused on were PARP cascade and JAK2/STAT3.   The methods utilized 
to investigate these pathways were western blotting for apoptotic and survival proteins as well as 
immunofluorescence to determine if the protein of interest relocated inside the cell. 
 
Specific Aim #2: To investigate the effect of Cuc IIa on the actin cytoskeleton. 
The purpose of this aim is to determine if Cuc IIa induces apoptosis through actions 
against the cytoskeleton, specifically the actin cytoskeleton.  Cucurbitacins of similar structure to 
Cuc IIa have shown to induce apoptosis through actions against the actin cytoskeleton.  We 
observed morphological changes of cancer cells as a confirmation of actin cytoskeletal disruption 
which causes cytotoxicity and cell death inhibiting cell locomotion and cellular division.  
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Chapter 5: Results 
Hypothesis: Cucurbitacin IIa induces cancer cell death through the activation of apoptotic 
pathways and actin clustering. 
Specific Aim #1: To investigate the cytotoxic action of Cuc IIa on cancer cells. – The 
experimental results I obtained support the conclusion that Cuc IIa shows induction of apoptosis 
through activation of caspase cascade and mitotic arrest independent of JAK2/STAT3 signaling 
pathway.  
Cuc IIa, a triterpenoid, shows anti-cancer potential.  Metabolic tests, especially MTT 
assays, are an important indicator of cell viability after the treatment of Cuc IIa.  Since formazan 
is only produced in live cells, the difference in concentration is a reliable method to detect cell 
death in Cuc treated cells as compared to non-treated cells (Hatok et al., 2009; Yung 1989; 
Denizot and Lang 1986).  It is with this point in mind that the results of the MTT assay show that 
Cuc IIa consistently killed cancer cells across H1299 cells, PC3 cells and CWR22-Rv1 cells 
(Figure 3).  The cytotoxic effect of Cuc IIa was compared to the amount of cell viability after 
treatment with Cisplatin.  Cisplatin is an anti-cancer drug that is well known to kill cancer cells.  
Cuc IIa also was compared to paclitaxel.  Comparing Cuc IIa to Cisplatin and Taxol revealed 
Cuc IIa to have a stronger cytotoxic activity (results not shown).  
From the MTT assay we were able to show that Cuc IIa decreases cell viability.  However it 
was not known how Cuc IIa affected cell proliferation over time and how soon Cuc IIa affected 
the cells.  In order to determine the continual effects of Cuc IIa, CWR22-Rv1 cells were split 
onto a 12-well plate at a starting density of 10,000 cells per well.  The cells were treated with 
Cuc IIa at 1 and 10μg/mL and grown over a period of eight days.  Each treatment was counted 
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using a Countess Hematocytometer (Invitrogen) on days 2, 4 and 8.  The media was changed and 
new treatment was added onto the respective wells on days 3, 5 and 7.  The number of cells 
counted was reflected in a graph showing Cuc IIa had an immediate effect on the cells treated 
(Figure 4).  Cuc IIa at 1μg/mL immediately reduced the amount of cells alive within the first 
48hr period of treatment.  Cuc IIa 10μg/mL had an even more dramatic effect on the cells 
showing double the amount of suppressed growth in the first 48hr treatment.  By counting the 
number of cells collected, we recorded a decrease in cell number after 24 hours of treatment, 
with nearly 50% decrease by 1μg/mL Cuc IIa treatment and 100% decrease by 10μg/mL Cuc IIa 
treatment.  It would appear that Cuc IIa at 10μg/mL prevented the carcinogenic cells from 
proliferating, supporting that the main mechanism of Cuc IIa effects is through actions on the 
mitotic phase of the cell cycle.  Since cells treated 10 μg/mL Cuc IIa never reached above 10,000 
cells (initially plated), these experiments suggest that the cells not only did not divide, but they 
also underwent cell death. 
Previous studies on Hemsleya amabilis extract, the active component of Cuc IIa, has shown 
that Cuc IIa has cytotoxic properties toward cancer cells.  However it is unknown what phase in 
the cell cycle that Cuc IIa has the greatest effect.  H1299 cells were grown to 60% confluence 
when the cells were treated with Cuc IIa at 10μg/mL for 16 hours.  After collecting and fixing 
the cells, the H1299 cells were stained with Propidium Iodide and run through a FlowScan flow 
cytometer to record the percentage of cells in a given cell cycle phase from a sample of 10,000 
cells.  The results of the flow cytometer showed that Cuc IIa had resulted in a reduced S-phase as 
well as an increased G2/M phase.  This would indicate that Cuc IIa arrests the cell prior to 
Mitosis in the G2/M phase.   
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CWR22Rv1 cells were treated with Cuc IIa 1μg/mL and 50μg/mL, respectively, and 
stained with anti-phospho-RhoA.  RhoA is a protein associated with the actin cytoskeleton 
(Ridley 2006), and is integral in the completion of cytokinesis (Li et al., 2010; Narumiya et al., 
2009).  RhoA is also well associated with the cytoskeletal arrangements observed in apoptosis 
(Chang and Lee 2006; Coleman and Olson 2002; Aznar and Lacal 2001).  Due to the close 
association with actin, we wonder if RhoA was affected by Cuc IIa treatment.  Since the 
aggregation of actin can be one effect of Cuc IIa to induce apoptosis, it is of interest to know if 
Cuc IIa will cause any change in RhoA.  From the immunofluorescent staining performed on 
Rv1 cells, we were able to determine that phospho-Rho A is clustered in a similar pattern as the 
actin clustering when treated with Cuc IIa (Figure 6).   
Not only is the activation of apoptotic pathways a prime target for cancer therapy, there is 
also an interest in targeting the deregulation of crucial cellular pathways one of which includes 
the MAPK signaling pathway.  There are many studies showing the MAPK pathway is a critical 
pathway crucial in a wide variety of cellular processes including proliferation, growth, migration 
and apoptosis, to name a few (Dhillon et al., 2007; Mebratu and Tesfaigzi 2009).  Of the MAPK 
pathways, p38 MAPK pathway has functions inducing apoptosis.  It has been discovered the p38 
MAPK pathway is disabled in many cancer cell lines (Coulthard et al., 2009).  Researchers have 
found that the p38 MAPK pathway is activated in cell lines treated with the cancer drugs 
Vincristine, Vinblastine, Taxol and Cisplatin (Dhillon et al., 2007).  It is theorized that apoptosis 
is induced through the activation of p38 MAPK.  We sought to determine if Cuc IIa induced a 
similar phosphorylation of p38 MAPK.  H1299 cells were grown to confluency and treated with 
Cuc IIa at 1, 10, and 50μg/mL followed by immunofluorescent staining using anti-phospho- p38 
MAPK (New England Biolabs).  In the immunofluorescent staining we expect to see an 
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increased staining for the Cuc IIa treated cells to indicate MAPK as an element of inducing 
apoptosis.  In the stained H1299 cells, we are able to see an increase in activated p38 MAPK 
clustering alongside actin fibers.  In Cuc IIa 0μg/mL cells, the stain for phospho-p38 MAPK was 
generally spread out and uniform throughout the cell.  In the Cuc IIa 1μg/mL treated cells, we 
were able to observe the activated p38 MAPK cluster following F-actin.  The clustering of 
phospho-p38 MAPK was increased as the concentration of Cuc IIa was increased.  The cells 
were also stained for actin using Fluorescin phalloidin (Promega) to cause actin fibers to 
fluoresce green.  The actin staining was used to further confirm the actin clustering properties of 
Cuc IIa observed in CWR22-Rv1 cells.  We also stained the nuclei blue with Hoechest as an 
image reference that allow nuclear/cytoplasm differentiation. 
JAK2 and STAT3 are activated when phosphorylated by the serine/threonine kinases on cell 
surface receptors.  These proteins are a part of the JAK pathway to increase cell survival signals 
while suppressing apoptotic signals.  A majority of Cucurbitacins induce apoptosis by inhibiting 
the JAK2/STAT3 pathway.  So, we performed western blot to determine if we could detect any 
change in JAK2/STAT3 expression level. 
Cell lysates were run onto a nitrocellulose membrane and probed for survival proteins JAK2 
and STAT3. The western blot staining for JAK2 and STAT3 along with the phosphorylated 
counterparts showed no consistent differences between treated and non-treated cells, an 
indication that Cuc IIa may not exert major effects on the JAK/STAT pathway (Figure 8A).  This 
result was supported by immunofluorescent light microscopy showing no redistribution of the 
STAT3 proteins in the cells (Figure 8B).  When activated, STAT3 is known to redistribute from 
cytoplasm to the nucleus.     
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The experimental results described above demonstrated that Cuc IIa reduces cell 
proliferation in a dose- and time-dependent manner, with the first effects seen within the first 48 
hours of treatment.  Through immunofluorescent staining of the actin regulatory protein RhoA, 
we can deduce one target of Cuc IIa to induce cell death was through the alteration of the 
cytoskeleton.  Flow cytometry analysis also confirmed the cells were arrested in the G2/Mitosis 
phase of the cell cycle.  With all of this data, we sought to confirm the changes of apoptotic 
proteins within the cell by Western blots. 
The lysates of H1299, PC3 and Rv1 cells were run on a Tris-Glycine gel then transferred to 
nitrocellulose membrane and blotted for the apoptotic proteins, e.g. Cleaved PARP and PARP.  
The caspases are a family of cysteine proteases responsible for the morphological changes 
exhibited in the apoptotic cell (Cohen 1997).  Caspase-9 is activated by activated receptors on 
the cell surface (Ghavami et al., 2009).  Then, caspase-3 is activated through cleavage and 
proceeds to cleave PARP, deactivating its DNA repair function (Gao et al., 2008; Shen et al., 
2004).  PARP is an enzyme that recognizes breaks in the DNA and is responsible for repairing 
these breaks (Boulares et al., 1999; Augustin et al., 2003).  The cleaved PARP was dramatically 
increased in cells treated with 50μg/mL Cuc IIa, while the full length PARP protein showed no 
change within the expression of all treatments. 
We also blotted for inhibitor of apoptosis, Survivin and mitotic proteins, Histone H3 and 
phospho-Histone H3 (Figure 9).  Histones are proteins that are responsible for condensing the 
DNA into bundles, named nucleosomes within the nucleus forming chromatin (Cheung et al., 
2000; Rosetto et al., 2010; Taby et al., 2010).  The histone proteins release their confirmation 
and open the DNA when they are active through the phosphorylation of histone H3.  Histones, 
H3 especially, are altered through phosphorylation as a way to make DNA accessible for cellular 
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processes such as mitosis, DNA repair, and apoptosis (Sawan and Herceg, 2010; Fullgrabe et al., 
2010).  We detected that phospho-Histone H3 was greatly reduced in cells treated with 50μg/mL 
Cuc IIa.  Survivin, on the other hand, showed a remarkable reduction in expression when cells 
were treated with 50μg/mL Cuc IIa.   
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Specific Aim #2: To investigate the effects of Cuc IIa on the actin cytoskeleton. – The 
experimental results I obtained support the conclusion that Cuc IIa induces apoptosis through 
alterations in cytoskeleton by clustering of actin molecules but not against the microtubule 
network.  
Our studies showed that Cuc IIa have cytotoxic effects on cells through a reduced cell 
proliferation in MTT assays.  To understand how cytoskeletal alterations may affect cell 
proliferation, CWR22-Rv1 cells transfected with green fluorescent protein tagged actin were 
treated with 10μg/mL Cuc IIa and recorded every fifteen minutes under the inverted fluorescent 
microscope for four hours.  We observed a drastic increase in actin clustering for cells treated 
with Cuc IIa as compared to the cells under no treatment (Figure 10).  The cells with no 
treatment continued to grow without showing any signs of a change in cell morphology.  
However, the Cuc IIa treated cells showed actin clustering over the four hour period as well as a 
change in the cell morphology.  As the treated cells were observed, we detected the cell 
shrinking and seeming to fold in on itself.  The effects on actin with Cuc IIa were reminiscent of 
that of Cucurbitacin B and E which also affect the cytoskeleton when treating cells in a similar 
manner. 
The very same treatment was performed for the NIH 3T3 cells (Figure 11).  These cells were 
set up on the inverted fluorescent microscope and were also treated with Cuc IIa for a four hour 
period to record a picture every fifteen minutes.  We observed similar results with the 3T3 cells 
as that with the CWR22-Rv1: cell shrinkage and drastic actin clustering.  These results suggested 
that clustering of the actin fibers is likely one mechanism that Cuc IIa harnesses for the induction 
of apoptosis. 
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Since Cuc IIa induced actin clustering in the cell, we sought out to determine if the effect 
could be reversed.  To do this, NIH 3T3 cells were grown and set up under the inverted 
fluorescent microscope to record a picture every fifteen minutes.  NIH 3T3 cells were treated 
with 50μg/mL Cuc IIa for two hours, after which Cuc IIa was removed.  The cells were washed 
and recorded for two more hours under normal growth media. The actin continued to show 
clustering under the microscope even after 2 hours following the removal of Cuc IIa (Figure 12). 
Many members of the cucurbitacin family have been shown to affect the cytoskeleton.  
Through our experiments we have shown that Cuc IIa has an effect on the actin, however we 
don’t know if Cuc IIa would also affect the tubulin portion of the cytoskeleton.  We grew 
CWR22-Rv1 cells on coverslips with RPMI 1640 growth media and treated with 50μg/mL Cuc 
IIa for 24 hours.  After 24 hours, the cells were fixed in paraformaldehyde and stained with anti-
α-tubulin to label microtubules and Rhodamine Phalloidin for filamentous actin.  We observed 
actin clustering, just as we discovered during the time lapse experiments (Figure 13).  However, 
Cuc IIa did not appear to show any discernible effects on microtubules when they were 
examined by anti-tubulin staining (Figure 13B).  While Cuc IIa has a dramatic effect on actin in 
the cell (Figure 13A), there appears to be no effect on the tubulin in the cell.  The lack of tubulin 
effects shows Cuc IIa to be different from other cucurbitacins, many of which effect the tubulin, 
as well as the actin in the cytoskeleton. 
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Chapter 6: Discussion 
 
Cuc IIa is the most recent compound to be discovered from the Cucurbitacin family, 
therefore it is expected to have similar apoptotic qualities as the Cucurbitacin family, such as the 
effects on JAK/STAT pathways.  It has been suggested that the inhibition of JAK2/STAT3 
underlies the apoptosis when cancer cells are treated with Cuc.  Sun et al (2005) showed that Cuc 
effectively inhibited cancer cell expansion only in STAT3-expressing cells.  While our study is 
consistent with the observations of Cuc effects on mitosis, we found that even though prostate 
cancer cells (CWR22Rv-1) and lung cancer cells (NCI-H1299) displayed JAK2/STAT3 
expression and activating phosphorylation, Cuc IIa still induced apoptosis without clearly 
inhibiting JAK2/STAT3 phosphorylation.  Cuc IIa also did not alter nuclear/cytoplasmic 
distribution of STAT3, as shown by Figure 8.  We showed that the cell cycle was disrupted with 
reduced phospho-Histone H3 and survivin. 
Our studies show that Cuc IIa differs from other Cucurbitacins in several interesting ways.  
As with other Cucurbitacins, Cuc IIa was found to suppress cancer cell growth based on cellular 
metabolism (Figure 3) and cell growth study (Figure 4).  It also disrupts the actin cytoskeleton by 
inducing non-reversible clustering of F-actin (Figure 12).  Whereas other members of the 
Cucurbitacin family have an effect on JAK2/STAT3 (Haritunians et al., 2008), Cuc IIa does not 
share this feature, instead induction of apoptosis involves Survivin and PARP, a cascade 
commonly targeted in chemotherapy drugs.  The expression of JAK2/STAT3 in treated cells 
remained evident compared to that of non-treated cells (Figure 8).  In regards to the cytoskeletal 
changes of Cuc IIa treated cells, we detected a reduction in phosphorylated RhoA.  RhoA is a 
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GTPase protein that is known to regulate the cytoskeleton among other functions (Aznar and 
Lacal, 2001; Ridley, 2006).   
Natural occurring medicinal products have made crucial contributions to anti-cancer 
therapies.  For example Paclitaxel is a taxane-based chemotherapy drug targeting mitotic 
microtubule cytoskeletons (Pezzuto, 1997).  Paclitaxel is originally isolated from the plant Taxus 
brevifolia Nutt acting on cancer cells by stabilizing microtubule cytoskeleton so that the 
filaments are not able to breakdown properly (Torres and Horwitz, 1998; Cassinelli et al., 2004).  
As the cell moves through mitosis, the cell is arrested at anaphase (Lanzi et al., 2001).  The 
arrested cell most often goes through apoptosis due to mitotic failure; however, some cells can 
complete mitosis and then undergo programmed cell death (Shi et al., 2008).  While many anti-
cancer drugs are designed to alter a single pathway or function, plant-derived drugs have been 
shown to induce apoptosis in various ways.  Also many plant derived drugs have shown to have 
a direct effect on cell death through the cytoskeletal proteins, namely microtubules and actin. 
In recent years, there has been an increased interest in plant-derived chemotherapy drugs due 
to the successes of the chemotherapeutics Taxol, Vincristine, and Vinblastine.  Vincristine and 
Vinblastine are two drugs derived from Catharanthus roseus.  These drugs have been successful 
in treating a large variety of cancers.  Also, plant derived chemotherapy drugs target multiple 
pathways and therefore appear to have a stronger cytotoxic effect on carcinogenic cells.  Many 
plant derived chemotherapy drugs have an added effect due to the pathways involved resulting in 
apoptosis. 
Recently discovered, cucurbitacins are a new class of drugs that are found in plants and roots 
throughout the planet.  Many cucurbitacins belong to a triterpenoid class of drugs that’s divided 
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into 26 categories ranging from Cuc A to Cuc S (Chen et al., 2008).  Researchers have found 
many of the cucurbitacins have cytotoxic properties geared toward cancer cells (e.g. Cuc B).  
Cuc family disrupts actin dynamics, probably by initiating two signaling cascade events in 
cancer cells.  First, it can inhibit JAK2/STAT3 phosphorylation thereby preventing cell 
proliferation.  Second, the failed cytokinesis activates apoptosis pathways, with reduced 
phosphorylation level of Histone H3 and increased chromatin damage.   
Compounds in the Cucurbitacin family are differentiated based on the chemical structure 
of the compound and it’s affect against cancer cells.  There have been many studies investigating 
a correlation between the chemical structure and the compounds anti-cancer activity.  It has been 
discovered that even one variation on a group off the side chain can indicate a Cucurbitacins 
activity.  Through chemical structure studies, Sun et al. (2005) have identified the side chains on 
carbon-11 and carbon-3 to be related to the JAK2 and STAT3 of cucurbitacins.  Through this 
study, Sun et al. found cucurbitacins lost anti-STAT3 activity due to the addition of a single 
hydroxyl group to carbon 11.  Sun et al. also found that cucurbitacins lost anti-JAK2 activity 
when the carbonyl group on carbon 3 was converted to a hydroxyl group.  Duncan et al. (1996) 
also performed chemical structure studies on various cucurbitacins to identify structural 
differences between cucurbitacins with anti-proliferative and actin-directed cytotoxicity, such as 
Cuc I and Cuc D.  In their studies they found the hydroxylation of carbon 23 along the 
cucurbitane skeleton eliminated the anti-proliferative and actin disrupting activity typical of 
many cucurbitacins. 
The actin cytoskeleton has a multitude of functions within the cells including cytokinesis, 
locomotion, and apoptosis (Symons & Mitchison 1991, Kavallaris 2010).  Actin is a structural 
molecule consisting of a globular, ATP binding protein that undergoes polymerization and de-
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polymerization in order to grow and shrink as filaments (Staiger & Blanchoin 2006; Watanabe, 
2010; Suarez-Huerta et al., 2000).  Actin is also a motile protein and essential for growth control 
and metastasis of tumor cells (Rao et al. 1999).  After the cell completes mitosis, cytokinesis 
occurs and new daughter cell results.  When actin is inhibited then the cell becomes arrested 
during the G2/M phase of the cell cycle thereby preventing cytokinesis.  When the cell is unable 
to divide it is directed into apoptosis. (Brangwynne 2008, Sánchez-Alcázar et al. 2007) 
A second cytoskeletal component, which is crucial to mitosis, is the microtubule network.  
Microtubules have multiple roles including cellular functions but especially important for 
chromatid alignment and separation during mitosis.  Microtubules are mobile as a result of 
alternating periods of elongation and shrinkage, known as dynamic instability.  It has been 
shown that many Cucurbitacins have an effect on the microtubules leading the cell to undergo 
apoptosis.  Cuc E, for example, stabilizes the microtubules preventing their shortening which 
draws chromatids back to the daughter cells.  The cell becomes arrested in mitosis and undergoes 
apoptosis as a result of the failed mitotic phase.  Through the studies we performed in the lab, it 
was clear that Cuc IIa had no effect on the microtubules.  From the immunofluorescent images 
where we probed for tubulin in Cuc IIa treated cells (Figure 13B), we were unable to detect any 
difference between the control and treated cells. 
The expression of survivin has two roles in the cell: inhibition of apoptosis and regulation of 
mitosis.  Survivin inhibits apoptosis through interference with caspase-9 preventing the cascade 
which leads to PARP cleavage and results in apoptosis due to unrepaired DNA damage (Li et al., 
1998; Andersen et al., 2007).  Survivin is required for the proper completion of cell division 
during mitosis, partly by ensuring the microtubules are properly attached to kinetochores 
(Anderson et al., 2007).   Many cancers have increased survivin expression as compared to 
 27 
 
normal tissues.  The increased survivin expression helps cancer cells to prevent apoptosis (Olie 
et al., 2000).  To better understand the cytotoxic effect that Cuc IIa exerts on the cancer cells, we 
investigated survivin expression in cell lysates.  We observed a dose dependent decrease in 
survivin expression level across the cell lines probed.  The downregulation of survivin suggested 
that the ability of cancer cells to prevent apoptosis during cell cycle arrest is being compromised.  
Therefore, due to the lack of survivin, the caspase cascade is initiated leading to apoptotic cell 
death. 
Overexpression of survivin and RhoA inhibition in CWR22Rv-1 cells protected cancer cells 
from Cuc IIa to some extent, suggesting that mitotic-related pathways involving survivin are 
potential targets to enhance Cuc IIa’s anti-cancer potential (which could be cooperating with p53 
and p21 pathways).  Therefore, not all Cuc family members induce apoptosis by directly 
inhibiting JAK2/STAT3 phosphorylation.  Rather, they could target the converging downstream 
elements such as survivin, indicating a broader benefit of applying Cuc derivatives. Thus, we 
hypothesize that Cuc IIa arrests cell cycle progression and results in cell death in the following 
working model (figure 14).   
The present study focused on Cuc IIa purified from the Chinese medicinal plant H. 
amabilis and demonstrated, for the first time, that Cuc IIa disrupted actin cytoskeleton and 
induced apoptosis through novel pathways involving survivin and PARP but independent of 
JAK2/STAT3 phosphorylation and distribution.  Future studies include investigate further the 
mechanisms by which Cuc IIa exerts its apoptotic functions toward cancerous cells.  
Mechanisms by which chemotherapeutics target include inhibiting survival pathways and 
activating apoptotic pathways.  One survival pathway of interest is the MAPK pathway.  It has 
been noted that the activation of p38 MAPK leads to apoptosis through the activation of the cell-
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cycle regulators p53 and p73 (Olson and Hallahan, 2004).  Since Cuc IIa induces apoptosis 
through downregulating survivin and PARP, it would be of interest to determine if Cuc IIa also 
induced apoptosis through p38 MAPK downstream activators.   
A new direction that can be pursued in regards to cytotoxicity of Cuc IIa is to investigate 
any association Cuc IIa may have with peripheral neuropathy.  Our lab has performed studies on 
peripheral neuropathy caused by Cisplatin and methods of preventing peripheral neuropathy.  
Since Cuc IIa is a new drug there is little information on the effects of Cuc treatment on neurons.  
Testing for any possible neuronal damage could lead to a better understanding of the 
mechanisms by which Cuc IIa induces cytotoxicity.   
Another possible study to pursue is to determine if Cuc IIa cytotoxicity specifically 
targets cancer cells or if cytotoxicity is non-specific.  All of the cells used were cancerous and 
non-cancerous cells were not applied in this study.  To further our understanding of Cuc IIa, we 
could compare the Cuc IIa treatment of cancer cells to non-cancer cells. 
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Chapter 7: Figures 
 
 
 
 
 
 
 
Fiure 1: Cucurbitacin basic structure, 9β-methyl-19-nor lanosta-5-ene, shared by all members 
of the cucurbitaceae family with differences being oxygen substitutions.(Chen et al., 2005) 
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Figure 2: Structure of Cucurbitacin IIa (hesmlecin A) 
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Figure 3: H1299, CWR22Rv-1 and PC3 cells treated in Cuc IIa 1, 10 and 100 μg/mL were 
observed to have an increased toxicity across the cell lines.  Cells were treated with Cuc IIa 
along with Taxol and Cisplatin we observed Cuc IIa had a consistent toxicity in carcinogenic 
cell lines. *P < 0.05 
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Figure 4: CWR22Rv-1 cells were plated at 10,000 cells/well and allowed to grow for a total 
of 8 days. Cells were treated on the 1st, 3rd and 5th days with Cuc IIa 0μg/mL, 1μg/mL and 
10μg/mL to be collected on the 2nd, 4th and 8th days. *p < 0.01. 
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Figure 5: H1299 cells treated with 10 μg/mL Cuc IIa, A) Cell phases G1, S and G2/M; B) 
Cell phase sub-G1 (apoptosis).   Cells were stained with Propidium Iodide and run through 
flow cytometer to record the phases of Cuc IIa treated cells and non-treated cells.  We 
recorded a majority of cells arresting within the mitotic phase of the cell cycle.  Along with 
the increase in apoptosis for Cuc IIa treated cells, we are able to conclude that Cuc IIa treated 
cells are arrested within the mitotic phase of the cell cycle.  *p < 0.01 
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Figure 6: CWR22Rv-1 cells were stained with anti-phospho-RhoA (red) and Hoechst 
staining to indicate nuclei (blue).  a-c: 0μg/mL Cuc IIa, d-f: 1μg/mL Cuc IIa, g-i: 50μg/mL 
Cuc IIa. a,d, g: phospho-RhoA, b, e, h: nuclei; c, f, i: merge. 
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Figure 7: H1299 cells stained with phospho-p38 MAPK (red), actin (green), and nuclei 
(blue).  Cells were grown on coverslips then treated with Cuc IIa for 2 days.  Cuc IIa 
treatments: 0μg/mL (a-d), 1μg/mL (e-h), 10μg/mL (i-l), and 50μg/mL (m-p). phospho-p38 
MAPK (a, e, i and m), nuclei (b, f, j and n), actin (c, g, k and o), and merge (d, h, l, and p).   
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Figure 8: A. Western blots of JAK2 and STAT3 proteins alongside phosphorylated 
counterparts.  GAPDH is used as control for equal loading of lysate proteins.  B. 
Immunofluorescence staining of actin (red; a,d), STAT3 (green; b, e), and merge (c, f). 
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Figure 9:  (left) 22Rv-1, PC3 and H1299 cells were treated with 1 μg/mL and 50 μg/mL Cuc 
IIa, respectively.  Resulting lysates were probed by western blots for cleaved and total PARP, 
Survivin, phospho- and Histone H3 with GAPDH to ensure equal loading of protein.  
(right) Densitometry analysis performed on Survivin, phospho-Histone H3, Histone H3, 
cleaved PARP, and PARP.  * p<0.01, ** p<0.05. 
  
 
 
38 
 
Panel A 
 
Panel B 
 
Figure 10: CWR22Rv-1 cells were transfected with EGFP-actin and observed over a period 
of 4 hours using an inverted fluorescent microscope.  Pictures were recorded every 15 
minutes after which images were compiled into a single figure for comparison.  Over the 
period of observation, there is a clear difference between the actin of non-treated cells as 
compared to treated cells.  Non-treated cells maintained a normal distribution of actin 
throughout the cell, while Cuc IIa treated cells showed an increased clustering of actin as the 
cells were exposed to treatment. Panel A:  Non-treated Cuc IIa, Panel B: Cuc IIa 10μgml. 
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Figure 11: NIH 3T3 cells transfected with EGFP-actin, treated with Cuc IIa at 10 μg/mL and 
observed over a period of 4 hours on inverted fluorescent microscope where images were 
taken every 15 minutes.  The images were compiled into a single figure for comparison of 
cells treated over time.  As with CWR22Rv-1 cells, we showed actin clusters of NIH 3T3 
cells treated with Cuc IIa at 10μg/mL. 
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Figure 12: NIH 3T3 cells were transfected with EGFP-Actin, set up under inverted 
fluorescent microscope to record images every 15 minutes for 4 hours and treated with Cuc 
IIa at 50 μg/mL.  As we expected, the actin clusters were detected as early as 1 hour (b).  The 
treatment was rinsed off using normal medium after 2 hours (c) exposure of Cuc IIa.  The 
cells were continued to be monitored for any indication that the normal actin morphology 
could be recovered from the treatment.  The images taken at hours 3 (d) and 4 (e) showed 
that cells are unable to be recovered after treatment with Cuc IIa. 
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Figure 13: CWR22Rv-1 cells were grown in culture medium and treated with 50 μg/mL Cuc 
IIa for 24 hours. Cells were stained for A) actin (red) and B) tubulin (red).  A) Actin staining 
for EGFP transfected cells; a-d non-treated cells; e-h Cuc IIa 50μg/mL.  B) Tubulin staining; 
a-c non-treated cells, d-f 50μg/mL Cuc IIa. 
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Figure 14: Schematic model illustrating the potential mechanism of Cuc IIa-induced 
apoptosis 
 
 
 
 
 
 
 
43 
 
References  
Aggarwal, B. B., Sethi, G., Ahn, K. S., Sandur, S. K., Pandey, M. K., Kunnumakkara, A. B., et 
al. (2006). Targeting signal-transducer-and-activator-of-transcription-3 for prevention and 
therapy of cancer: Modern target but ancient solution. Annals of New York Academy of 
Sciences, 1091, 151-169. 
Aggarwal, B. B., Kunnumakkara, A. B., Harikumar, K. B., Gupta, S. R., Tharakan, S. T., Koca, 
C., et al. (2009). Signal transducer and activator of transcription-3, inflammation, and 
cancer: How intimate is the relationship? Annals of the New York Academy of Sciences, 
1171, 59-76.  
Andersen, M. H., Svane, I. M., Becker, J. C., & Straten, P. T. (2007). The universal character of 
the tumor-associated antigen survivin. Clinical Cancer Research : An Official Journal of the 
American Association for Cancer Research, 13(20), 5991-5994. doi:10.1158/1078-
0432.CCR-07-0686  
Augustin, A., Spenlehauer, C., Dumond, H., Menissier-De Murcia, J., Piel, M., Schmit, A. C., et 
al. (2003). PARP-3 localizes preferentially to the daughter centriole and interferes with the 
G1/S cell cycle progression. Journal of Cell Science, 116(Pt 8), 1551-1562.  
Aznar, S., & Lacal, J. C. (2001). Rho signals to cell growth and apoptosis. Cancer Letters, 
165(1), 1-10.  
Battle, T. E., & Frank, D. A. (2002). The role of STATs in apoptosis. Current Molecular 
Medicine, 2(4), 381-392.  
 
 
44 
 
Benekli, M., Baumann, H., & Wetzler, M. (2009). Targeting signal transducer and activator of 
transcription signaling pathway in leukemias. Journal of Clinical Oncology : Official 
Journal of the American Society of Clinical Oncology, 27(26), 4422-4432. 
doi:10.1200/JCO.2008.21.3264  
Bhalla, K. N. (2003). Microtubule-targeted anticancer agents and apoptosis. Oncogene, 22(56), 
9075-9086.  
Boulares, A. H., Yakovlev, A. G., Ivanova, V., Stoica, B. A., Wang, G., Iyer, S., et al. (1999). 
Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. caspase 3-resistant 
PARP mutant increases rates of apoptosis in transfected cells. The Journal of Biological 
Chemistry, 274(33), 22932-22940.  
Brabec, V., & Leng, M. (1993). DNA interstrand cross-links of trans-
diamminedichloroplatinum(II) are preferentially formed between guanine and 
complementary cytosine residues. Proceedings of the National Academy of Sciences of the 
United States of America, 90(11), 5345-5349. 
Brangwynne, C. P., Koenderink, G. H., MacKintosh, F. C., & Weitz, D. A. (2008). 
Nonequilibrium microtubule fluctuations in a model cytoskeleton. Physical Review Letters, 
100(11), 118104. 
Bromberg, J., & Darnell, J. E.,Jr. (2000). The role of STATs in transcriptional control and their 
impact on cellular function. Oncogene, 19(21), 2468-2473. doi:10.1038/sj.onc.1203476  
 
 
45 
 
Brozovic, A., & Osmak, M. (2006). Activation of mitogen-activated protein kinases by cisplatin 
and their role in cisplatin-resistance. Cancer Letters, 251, 1-16. 
Cagnol, S., & Chambard, J. C. (2010). ERK and cell death: Mechanisms of ERK-induced cell 
death--apoptosis, autophagy and senescence. The FEBS Journal, 277(1), 2-21. 
doi:10.1111/j.1742-4658.2009.07366.x  
Calo, V., Migliavacca, M., Bazan, V., Macaluso, M., Buscemi, M., Gebbia, N., et al. (2003). 
STAT proteins: From normal control of cellular events to tumorigenesis. Journal of Cellular 
Physiology, 197(2), 157-168. doi:10.1002/jcp.10364  
Cassinelli, G., Supino, R., Zuco, V., Lanzi, C., Scovassi, A. I., Semple, S. C., et al. (2004). Role 
of c-myc protein in hormone refractory prostate carcinoma: Cellular response to paclitaxel. 
Biochemical Pharmacology, 68, 923-931. 
Chang, Z. F., & Lee, H. H. (2006). RhoA signaling in phorbol ester-induced apoptosis. Journal 
of Biomedical Science, 13(2), 173-180. doi:10.1007/s11373-005-9056-4 
Chen, J. C., Chiu, M. H., Nie, R. L., Cordell, G. A., & Qiu, S. X. (2005). Cucurbitacins and 
cucurbitane glycosides: Structures and biological activities. Natural Product Reports, 22, 
386-399.  
Cheung, P., Allis, C. D., & Sassone-Corsi, P. (2000). Signaling to chromatin through histone 
modifications. Cell, 103, 263-271.  
Cohen, G. M. (1997). Caspases: The executioners of apoptosis. The Biochemical Journal, 326, 1-
16.  
 
 
46 
 
Coleman, M. L., & Olson, M. F. (2002). Rho GTPase signalling pathways in the morphological 
changes associated with apoptosis. Cell Death and Differentiation, 9(5), 493-504. 
doi:10.1038/sj/cdd/4400987  
Coulthard, L. R., White, D. E., Jones, D. L., McDermott, M. F., & Burchill, S. A. (2009). 
p38(MAPK): Stress responses from molecular mechanisms to therapeutics. Trends in 
Molecular Medicine, 15(8), 369-379. doi:10.1016/j.molmed.2009.06.005  
Denizot, F. & Lang, R. (1986). Rapid colorimetric assay for cell growth and survival: 
Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. 
Journal of Immunological Methods, 89, 271-277. 
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007). MAP kinase signalling pathways in 
cancer. Oncogene, 26(22), 3279-3290. doi:10.1038/sj.onc.1210421  
Duncan, K. L. K., Duncan, M. D., Alley, M. C., & Sausville, E. A. (1996). Cucurbitacin E-
induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells. 
Biochemical Pharmacology, 52, 1553-1560.  
Duncan, M. D., & Duncan, K. L. K. (1997). Cucurbitacin E targets proliferating endothelia. 
Journal of Surgical Research, 69, 55-60.  
Escandell, J. M., Kaler, P., Recio, M. C., Sasazuki, T., Shirasawa, S., Augenlicht, L., et al. 
(2008). Activated kRas protects colon cancer cells from cucurbitacin-induced apoptosis: 
The role of p53 and p21. Biochemical Pharmacology, 76(2), 198-207.  
 
 
47 
 
Evan, G. I., & Vousden, K. H. (2001). Proliferation, cell cycle and apoptosis in cancer. Nature, 
411, 342-348.  
Fullgrabe, J., Hajji, N., & Joseph, B. (2010). Cracking the death code: Apoptosis-related histone 
modifications. Cell Death and Differentiation, 17(8), 1238-1243. doi:10.1038/cdd.2010.58  
Gao, Y., Ordas, R., Klein, J. D., & Price, S. R. (2008). Regulation of caspase-3 activity by 
insulin in skeletal muscle cells involves both PI3-kinase and MEK-1/2. Journal of Applied 
Physiology (Bethesda, Md.: 1985), 105(6), 1772-1778.  
Gascoigne, K. E., & Taylor, S. S. (2009). How do anti-mitotic drugs kill cancer cells? Journal of 
Cell Science, 122(Pt 15), 2579-2585. doi:10.1242/jcs.039719  
Ghavami, S., Hashemi, M., Ande, S. R., Yeganeh, B., Xiao, W., Eshraghi, M., et al. (2009). 
Apoptosis and cancer: Mutations within caspase genes. Journal of Medical Genetics, 46(8), 
497-510. doi:10.1136/jmg.2009.066944  
Gibb, R. K., M.D., Taylor, D. D., Ph.D., Wan, T., M.S., O'Connor, D. M., M.D., Doering, D. L., 
M.D., & Gerçel-Taylor, Ç., Ph.D. (1997). Apoptosis as a measure of chemosensitivity to 
cisplatin and taxol therapy in ovarian cancer cell lines. Gynecologic Oncology, 65, 13-22. 
Glienke, W., Maute, L., Wicht, J., & Bergmann, L. (2010). Curcumin inhibits constitutive 
STAT3 phosphorylation in human pancreatic cancer cell lines and downregulation of 
survivin/BIRC5 gene expression. Cancer Investigation, 28(2), 166-171.  
 
 
48 
 
Graness, A., Poli, V., & Goppelt-Struebe, M. (2006). STAT3-independent inhibition of 
lysophosphatidic acid-mediated upregulation of connective tissue growth factor (CTGF) by 
cucurbitacin I. Biochemical Pharmacology, 72, 32-41.  
Hanahan, D. & Weinberg, R. (2000). The Hallmarks of Cancer. Cell, 100, 57-70. 
Haritunians, T., Gueller, S., Zhang, L., Badr, R., Yin, D., Xing, H., et al. (2008). Cucurbitacin B 
induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid 
leukemia cells. Leukemia Research, 32, 1366-1373.  
Hatok, J., Babusikova, R., Matakova, T., Mistuna, D., Dobrota, D., & Racay, P. (2009). In vitro 
assays for the evaluation of drug resistance in tumor cells. Clinical and Experimental 
Medicine, 9, 1-7. 
Imada, K., & Leonard, W. J. (2000). The jak-STAT pathway. Molecular Immunology, 37(1-2), 
1-11.  
Johnstone, R. W., Ruefli, A. A., & Lowe, S. W. (2002). Apoptosis: A link between cancer 
genetics and chemotherapy. Cell, 108, 153-164.  
Jordan, M. A., & Wilson, L. (2004). Microtubules as a target for anticancer drugs. Nature 
Reviews.Cancer, 4(4), 253-265. doi:10.1038/nrc1317  
Kavallaris, M. (2010). Microtubules and resistance to tubulin-binding agents. Nature 
Reviews.Cancer, 10(3), 194-204.  
 
 
49 
 
Lanzi, C., Cassinelli, G., Cuccuru, G., Supino, R., Zuco, V., Ferlini, C., et al. (2001). Cell cycle 
checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells. The 
Prostate, 48, 254-264.  
Leonard, W. J. (2001). Role of jak kinases and STATs in cytokine signal transduction. 
International Journal of Hematology, 73(3), 271-277.  
Li, F., Ambrosini, G., Chu, E. Y., Plescia, J., Tognin, S., Marchisio, P. C., et al. (1998). Control 
of apoptosis and mitotic spindle checkpoint by survivin. Nature, 396, 580-584.  
Li, J., Wang, J., Jiao, H., Liao, J., & Xu, X. (2010). Cytokinesis and cancer: Polo loves ROCK'n' 
rho(A). Journal of Genetics and Genomics = Yi Chuan Xue Bao, 37(3), 159-172. 
doi:10.1016/S1673-8527(09)60034-5  
Liu, J. J., Lin, M., Yu, J. Y., Liu, B., & Bao, J. K. (2011). Targeting apoptotic and autophagic 
pathways for cancer therapeutics. Cancer Letters, 300(2), 105-114. 
doi:10.1016/j.canlet.2010.10.001 
Longley, D., & Johnston, P. (2005). Molecular mechanisms of drug resistance. Journal of 
Pathology, 205, 275-292.  
Maddika, S., Ande, S. R., Panigrahi, S., Paranjothy, T., Weglarczyk, K., Zuse, A., et al. (2007). 
Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer 
therapy. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and 
Anticancer Chemotherapy, 10(1-2), 13-29. doi:10.1016/j.drup.2007.01.003  
 
 
50 
 
Maloney, K. N., Fujita, M., Eggert, U. S., Schroeder, F. C., Field, C. M., Mitchison, T. J., et al. 
(2008). Actin-aggregating cucurbitacins from physocarpus capitatus. Journal of Natural 
Products, 71, 1927-1929.  
Mebratu, Y., & Tesfaigzi, Y. (2009). How ERK1/2 activation controls cell proliferation and cell 
death: Is subcellular localization the answer? Cell Cycle (Georgetown, Tex.), 8(8), 1168-
1175.  
Momma, K., Masuzawa, Y., Nakai, N., Chujo, M., Murakami, A., Kioka, N., et al. (2008). Direct 
interaction of cucurbitacin E isolated from alsomitra macrocarpa to actin filament. 
Cytotechnology, 56, 33-39.  
Mukherjee, A. K., Basu, S., Sarkar, N., & Ghosh, A. C. (2001). Advances in cancer therapy with 
plant based natural products. Current Medicinal Chemistry, 8(12), 1467-1486.  
Narumiya, S., Tanji, M., & Ishizaki, T. (2009). Rho signaling, ROCK and mDia1, in 
transformation, metastasis and invasion. Cancer Metastasis Reviews, 28(1-2), 65-76. 
doi:10.1007/s10555-008-9170-7  
Ndozangue-Touriguine, O., Hamelin, J., & Bréard. (2008). Cytoskeleton and apoptosis. 
Biochemical Pharmacology, 76, 11-18.  
Nefedova, Y., Nagaraj, S., Rosenbauer, A., Muro-Cacho, C., Sebti, S. M., & Gabrilovich, D. I. 
(2005). Regulation of dendritic cell differentiation and antitumor immune response in cancer 
by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and 
activators of transcription 3 pathway. Cancer Research, 65(20), 9525-9535. 
 
 
51 
 
Olie, R. A., Simões-Wüst, A. P., Baumann, B., Leech, S. H., Fabbro, D., Stahel, R. A., et al. 
(2000). A novel antisense oligonucleotide targeting survivin expression induces apoptosis 
and sensitizes lung cancer cells to chemotherapy. Cancer Research, 60, 2805-2809.  
Oliver, F. J., de la Rubia, G., Rolli, V., Ruiz-Ruiz, M. C., de Murcia, G., & Murcia, J. M. (1998). 
Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. lesson from an 
uncleavable mutant. The Journal of Biological Chemistry, 273(50), 33533-33539.  
Olson, J. M., & Hallahan, A. R. (2004). p38 MAP kinase: A convergence point in cancer 
therapy. Trends in Molecular Medicine, 10(3), 125-129. doi:10.1016/j.molmed.2004.01.007  
Pezzuto, J. M. (1997). Plant-derived anticancer agents. Biochemical Pharmacology, 53, 121-133.  
Rao, J. Y., Jin, Y. S., Zheng, Q., Cheng, J., Tai, J., & Hemstreet, G. P., III. (1999). Alterations of 
the actin polymerization status as an apoptotic morphological effector in HL-60 cells. 
Journal of Cellular Biochemistry, 75, 686-697. 
Ridley, A. J. (2006). Rho GTPases and actin dynamics in membrane protrusions and vesicle 
trafficking. Trends in Cell Biology, 16(10), 522-529. doi:10.1016/j.tcb.2006.08.006  
Rios, J. L., Recio, M. C., Escandell, J. M., & Andujar, I. (2009). Inhibition of transcription 
factors by plant-derived compounds and their implications in inflammation and cancer. 
Current Pharmaceutical Design, 15(11), 1212-1237.  
Rossetto, D., Truman, A. W., Kron, S. J., & Cote, J. (2010). Epigenetic modifications in double-
strand break DNA damage signaling and repair. Clinical Cancer Research : An Official 
 
 
52 
 
Journal of the American Association for Cancer Research, 16(18), 4543-4552. 
doi:10.1158/1078-0432.CCR-10-0513  
Sanchez-Alcazar, J. A., Rodriguez-Hernandez, A., Cordero, M. D., Fernandez-Ayala, D. J., 
Brea-Calvo, G., Garcia, K., et al. (2007). The apoptotic microtubule network preserves 
plasma membrane integrity during the execution phase of apoptosis. Apoptosis : An 
International Journal on Programmed Cell Death, 12(7), 1195-1208.  
Sawan, C., & Herceg, Z. (2010). Histone modifications and cancer. Advances in Genetics, 70, 
57-85. doi:10.1016/B978-0-12-380866-0.60003-4  
Shen, S. C., Ko, C. H., Tseng, S. W., Tsai, S. H., & Chen, Y. C. (2004). Structurally related 
antitumor effects of flavanones in vitro and in vivo: Involvement of caspase 3 activation, 
p21 gene expression, and reactive oxygen species production. Toxicology and Applied 
Pharmacology, 197(2), 84-95. doi:10.1016/j.taap.2004.02.002  
Shi, J., Orth, J. D., & Mitchison, T. (2008). Cell type variation in responses to antimitotic drugs 
that target microtubules and kinesin-5. Cancer Research, 68(9), 3269-3276.  
Shi, X., Franko, B., Frantz, C., Amin, H. M., & Lai, R. (2006). JSI-124 (cucurbitacin I) inhibits 
janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates 
nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive 
anaplastic large cell lymphoma cells. British Journal of Haematology, 135(1), 26-32. 
doi:10.1111/j.1365-2141.2006.06259.x  
 
 
53 
 
Staiger, C. J., & Blanchoin, L. (2006). Actin dynamics: Old friends with new stories. Current 
Opinion in Plant Biology, 9(6), 554-562.  
Stepkowski, S. M., Chen, W., Ross, J. A., Nagy, Z. S., & Kirken, R. A. (2008). STAT3: An 
important regulator of multiple cytokine functions. Transplantation, 85(10), 1372-1377.  
Suarez-Huerta, N., Mosselmans, R., Dumont, J. E., & Robaye, B. (2000). Actin 
depolymerization and polymerization are required during apoptosis in endothelial cells. 
Journal of Cellular Physiology, 184, 239-245.  
Sun, J., Blaskovich, M. A., Jove, R., Livingston, S. K., Coppola, D., & Sebti, S. M. (2005). 
Cucurbitacin Q: A selective STAT3 activation inhibitor with potent antitumor activity. 
Oncogene, 24(20), 3236-3245.  
Symons, M. H., & Mitchison, T. J. (1999). Control of actin polymerization in live and 
permeabilized fibroblasts. The Journal of Cell Biology, 114(3), 503-513.  
Taby, R., & Issa, J. P. (2010). Cancer epigenetics. CA: A Cancer Journal for Clinicians, 60(6), 
376-392. doi:10.3322/caac.20085  
Tannin-Spitz, T., Bergman, M., & Grossman, S. (2007). Cucurbitacin glucosides: Antioxidant 
and free-radical scavenging activities. Biochemical and Biophysical Research 
Communications, 364, 181-186.  
Tennant, D. A., Duran, R. V., & Gottlieb, E. (2010). Targeting metabolic transformation for 
cancer therapy. Nature Reviews.Cancer, 10(4), 267-277.  
 
 
54 
 
Thoennissen, N. H., Iwanski, G. B., Doan, N. B., Okamoto, R., Lin, P., Abbassi, S., et al. (2009). 
Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates 
antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Research, 69(14), 
5876-5884.  
Torres, K., & Horwitz, S. B. (1998). Mechanisms of taxol-induced cell death are concentration 
dependent. Cancer Research, 58(16), 3620-3626. 
Watanabe, N. (2010). Inside view of cell locomotion through single-molecule: Fast F-/G-actin 
cycle and G-actin regulation of polymer restoration. Proceedings of the Japan 
Academy.Series B, Physical and Biological Sciences, 86(1), 62-83.  
Wu, J., Wu, Y., & Yang, B. B. (2002). Anticancer activity of hemsleya amabilis extract. Life 
Sciences, 71(18), 2161-2170.  
Yung, W. (1989). In vitro chemosensitivity testing and its clinical application in human gliomas. 
Neurosurgical Review, 12, 197-203. 
